Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common form of lung cancer in the United States. Immunotherapies and cytotoxic chemotherapies used to treat advanced NSCLC carry a substantial risk of adverse events (AEs), but real-world data on the incidence and costs associated with the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Engel-Nitz, Nicole M., Johnson, Michael P., Bunner, Scott H., Ryan, Kellie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391087/
https://www.ncbi.nlm.nih.gov/pubmed/32463768
http://dx.doi.org/10.18553/jmcp.2020.26.6.729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391087/
https://www.ncbi.nlm.nih.gov/pubmed/32463768
http://dx.doi.org/10.18553/jmcp.2020.26.6.729

Ejemplares similares